Gilead Sciences, Inc.

Filing receipts

“28 Interest Expense and Other (Income) Expense, Net The following table summarizes our Interest expense and Other (income) expense, net and period-over-period changes: Three Months Ended March 31, (in millions, except percentages) 2026 2025 Change Interest expense $ 240 $ 260 (8) % Other (income) expense, net $ (235) $ 328 NM (Gain) loss from equity securities, net $ (142) $ 426 NM Interest income $ (95) $ (94) 1 % Other, net $ 2 $ (4) NM _______________________________ NM - Not Meaningful Interest expense decreased 8% to $240 million for the three months ended March 31, 2026, compared to the same period in 2025, primarily due to lower debt balances.”

“The increase was primarily due to: • Net unrealized gains from equity securities compared to net unrealized losses in 2025; • Higher product sales; and • Lower acquired in-process research and development (“IPR&D”) expenses; partially offset by • Higher income tax expense; and • Higher selling, general and administrative expenses.”

“The increase was primarily due to: • Net unrealized gains from equity securities compared to net unrealized losses in 2025; • Higher product sales; and • Lower acquired in-process research and development (“IPR&D”) expenses; partially offset by • Higher income tax expense;”